Small Molecule — Pharmacokinetics Comparison
Side-by-side comparison of 38 Small Molecule drugs with interactive PK simulators. Compare dosing, routes of administration, indications, and pharmacokinetic profiles.
| Drug | Route | Model Type | Indication | Therapeutic Area | Simulator |
|---|---|---|---|---|---|
| Asundexian FXIa Inhibitor | Oral | PK/PD | Anticoagulation | Cardiology | Open → |
| Betamethasone Metabolite | IV/IM | PopPK | Inflammation/Preterm Labor | Immunology | Open → |
| Betamethasone NCA | IV/IM | NCA | Inflammation | Immunology | Open → |
| Biktarvy (Bictegravir/Emtricitabine/TAF) | Oral | 1-CMT PopPK | HIV-1 infection | Infectious Disease | Open → |
| Cyclosporine | Oral | PopPK | Organ Transplant Rejection | Transplant | Open → |
| Digoxin | Oral | PopPK | Heart Failure / Atrial Fibrillation | Cardiology | Open → |
| Eliquis (Apixaban) | Oral | 1-CMT PopPK | Stroke prevention in atrial fibrillation | Cardiology | Open → |
| Entresto (Sacubitril/Valsartan) | Oral | 2-CMT PopPK | Heart failure with reduced ejection fraction | Cardiology | Open → |
| Farxiga (Dapagliflozin) | Oral | 1-CMT PopPK | Type 2 diabetes mellitus | Endocrinology | Open → |
| Ganciclovir | IV/Oral | PK/PD | CMV Infection | Infectious Disease | Open → |
| Ibrance (Palbociclib) | Oral | 1-CMT PopPK | HR+/HER2- metastatic breast cancer | Oncology | Open → |
| Imatinib | Oral | PopPK | CML / GIST | Oncology | Open → |
| Imbruvica (Ibrutinib) | Oral | 1-CMT PopPK | Chronic lymphocytic leukemia | Oncology | Open → |
| Infigratinib | Oral | PopPK | Cholangiocarcinoma | Oncology | Open → |
| Invega Sustenna (Paliperidone Palmitate) | IM (LAI) | 2-CMT PopPK | Schizophrenia | Psychiatry | Open → |
| Jardiance (Empagliflozin) | Oral | 1-CMT PopPK | Type 2 diabetes mellitus | Endocrinology | Open → |
| Lynparza (Olaparib) | Oral | 1-CMT PopPK | BRCA-mutated ovarian cancer | Oncology | Open → |
| Maternal-Fetal | IV | PopPK | Maternal-Fetal Medicine | Obstetrics | Open → |
| Mycophenolate | Oral | PopPK | Organ Transplant Rejection | Transplant | Open → |
| Ofev (Nintedanib) | Oral | 1-CMT PopPK | Idiopathic pulmonary fibrosis | Pulmonology | Open → |
| Oncology Dose Selection Tool | Oral | PK/PD | Solid Tumors | Oncology | Open → |
| Oxacillin Neonatal | IV | PopPK | MSSA Infections (Neonates) | Infectious Disease | Open → |
| Paxlovid (Nirmatrelvir/Ritonavir) | Oral | 1-CMT PopPK | COVID-19 treatment | Infectious Disease | Open → |
| Pomalyst (Pomalidomide) | Oral | 1-CMT PopPK | Multiple myeloma | Oncology | Open → |
| PopPK Framework | Various | PopPK | Drug Development | Platform | Open → |
| Revlimid (Lenalidomide) | Oral | 1-CMT PopPK | Multiple myeloma | Oncology | Open → |
| Rinvoq (Upadacitinib) | Oral | 1-CMT PopPK | Rheumatoid arthritis | Immunology | Open → |
| Risperidone D2RO | Oral/LAI | PK/PD | Schizophrenia | CNS | Open → |
| Tacrolimus | Oral | PopPK | Organ Transplant | Transplant | Open → |
| Tagrisso (Osimertinib) | Oral | 1-CMT PopPK | EGFR-mutated non-small cell lung cancer | Oncology | Open → |
| Trikafta (Elexacaftor/Tezacaftor/Ivacaftor) | Oral | 1-CMT PopPK | Cystic fibrosis | Pulmonology | Open → |
| Verzenio (Abemaciclib) | Oral | 1-CMT PopPK | HR+/HER2- metastatic breast cancer | Oncology | Open → |
| Voriconazole IV | IV | PopPK | Invasive Fungal Infections | Infectious Disease | Open → |
| Vyndaqel (Tafamidis) | Oral | 1-CMT PopPK | Transthyretin amyloid cardiomyopathy | Cardiology | Open → |
| Warfarin | Oral | PK/PD | Anticoagulation | Cardiology | Open → |
| Weight-HbA1c-Glucose | Oral | PK/PD | Obesity/T2DM | Metabolic | Open → |
| Xarelto (Rivaroxaban) | Oral | 1-CMT PopPK | Stroke prevention in atrial fibrillation | Cardiology | Open → |
| Xtandi (Enzalutamide) | Oral | 1-CMT PopPK | Metastatic castration-resistant prostate cancer | Oncology | Open → |
Individual Drug Profiles
Asundexian FXIa Inhibitor
- Route
- Oral
- Model Type
- PK/PD
- Indication
- Anticoagulation
- Therapeutic Area
- Cardiology
Betamethasone Metabolite
- Route
- IV/IM
- Model Type
- PopPK
- Indication
- Inflammation/Preterm Labor
- Therapeutic Area
- Immunology
Betamethasone NCA
- Route
- IV/IM
- Model Type
- NCA
- Indication
- Inflammation
- Therapeutic Area
- Immunology
Biktarvy (Bictegravir/Emtricitabine/TAF)
- Route
- Oral
- Model Type
- 1-CMT PopPK
- Indication
- HIV-1 infection
- Therapeutic Area
- Infectious Disease
Cyclosporine
- Route
- Oral
- Model Type
- PopPK
- Indication
- Organ Transplant Rejection
- Therapeutic Area
- Transplant
Digoxin
- Route
- Oral
- Model Type
- PopPK
- Indication
- Heart Failure / Atrial Fibrillation
- Therapeutic Area
- Cardiology
Eliquis (Apixaban)
- Route
- Oral
- Model Type
- 1-CMT PopPK
- Indication
- Stroke prevention in atrial fibrillation
- Therapeutic Area
- Cardiology
Entresto (Sacubitril/Valsartan)
- Route
- Oral
- Model Type
- 2-CMT PopPK
- Indication
- Heart failure with reduced ejection fraction
- Therapeutic Area
- Cardiology
Farxiga (Dapagliflozin)
- Route
- Oral
- Model Type
- 1-CMT PopPK
- Indication
- Type 2 diabetes mellitus
- Therapeutic Area
- Endocrinology
Ganciclovir
- Route
- IV/Oral
- Model Type
- PK/PD
- Indication
- CMV Infection
- Therapeutic Area
- Infectious Disease
Ibrance (Palbociclib)
- Route
- Oral
- Model Type
- 1-CMT PopPK
- Indication
- HR+/HER2- metastatic breast cancer
- Therapeutic Area
- Oncology
Imbruvica (Ibrutinib)
- Route
- Oral
- Model Type
- 1-CMT PopPK
- Indication
- Chronic lymphocytic leukemia
- Therapeutic Area
- Oncology
Infigratinib
- Route
- Oral
- Model Type
- PopPK
- Indication
- Cholangiocarcinoma
- Therapeutic Area
- Oncology
Invega Sustenna (Paliperidone Palmitate)
- Route
- IM (LAI)
- Model Type
- 2-CMT PopPK
- Indication
- Schizophrenia
- Therapeutic Area
- Psychiatry
Jardiance (Empagliflozin)
- Route
- Oral
- Model Type
- 1-CMT PopPK
- Indication
- Type 2 diabetes mellitus
- Therapeutic Area
- Endocrinology
Lynparza (Olaparib)
- Route
- Oral
- Model Type
- 1-CMT PopPK
- Indication
- BRCA-mutated ovarian cancer
- Therapeutic Area
- Oncology
Maternal-Fetal
- Route
- IV
- Model Type
- PopPK
- Indication
- Maternal-Fetal Medicine
- Therapeutic Area
- Obstetrics
Mycophenolate
- Route
- Oral
- Model Type
- PopPK
- Indication
- Organ Transplant Rejection
- Therapeutic Area
- Transplant
Ofev (Nintedanib)
- Route
- Oral
- Model Type
- 1-CMT PopPK
- Indication
- Idiopathic pulmonary fibrosis
- Therapeutic Area
- Pulmonology
Oncology Dose Selection Tool
- Route
- Oral
- Model Type
- PK/PD
- Indication
- Solid Tumors
- Therapeutic Area
- Oncology
Oxacillin Neonatal
- Route
- IV
- Model Type
- PopPK
- Indication
- MSSA Infections (Neonates)
- Therapeutic Area
- Infectious Disease
Paxlovid (Nirmatrelvir/Ritonavir)
- Route
- Oral
- Model Type
- 1-CMT PopPK
- Indication
- COVID-19 treatment
- Therapeutic Area
- Infectious Disease
Pomalyst (Pomalidomide)
- Route
- Oral
- Model Type
- 1-CMT PopPK
- Indication
- Multiple myeloma
- Therapeutic Area
- Oncology
PopPK Framework
- Route
- Various
- Model Type
- PopPK
- Indication
- Drug Development
- Therapeutic Area
- Platform
Revlimid (Lenalidomide)
- Route
- Oral
- Model Type
- 1-CMT PopPK
- Indication
- Multiple myeloma
- Therapeutic Area
- Oncology
Rinvoq (Upadacitinib)
- Route
- Oral
- Model Type
- 1-CMT PopPK
- Indication
- Rheumatoid arthritis
- Therapeutic Area
- Immunology
Risperidone D2RO
- Route
- Oral/LAI
- Model Type
- PK/PD
- Indication
- Schizophrenia
- Therapeutic Area
- CNS
Tacrolimus
- Route
- Oral
- Model Type
- PopPK
- Indication
- Organ Transplant
- Therapeutic Area
- Transplant
Tagrisso (Osimertinib)
- Route
- Oral
- Model Type
- 1-CMT PopPK
- Indication
- EGFR-mutated non-small cell lung cancer
- Therapeutic Area
- Oncology
Trikafta (Elexacaftor/Tezacaftor/Ivacaftor)
- Route
- Oral
- Model Type
- 1-CMT PopPK
- Indication
- Cystic fibrosis
- Therapeutic Area
- Pulmonology
Verzenio (Abemaciclib)
- Route
- Oral
- Model Type
- 1-CMT PopPK
- Indication
- HR+/HER2- metastatic breast cancer
- Therapeutic Area
- Oncology
Voriconazole IV
- Route
- IV
- Model Type
- PopPK
- Indication
- Invasive Fungal Infections
- Therapeutic Area
- Infectious Disease
Vyndaqel (Tafamidis)
- Route
- Oral
- Model Type
- 1-CMT PopPK
- Indication
- Transthyretin amyloid cardiomyopathy
- Therapeutic Area
- Cardiology
Weight-HbA1c-Glucose
- Route
- Oral
- Model Type
- PK/PD
- Indication
- Obesity/T2DM
- Therapeutic Area
- Metabolic
Xarelto (Rivaroxaban)
- Route
- Oral
- Model Type
- 1-CMT PopPK
- Indication
- Stroke prevention in atrial fibrillation
- Therapeutic Area
- Cardiology
Xtandi (Enzalutamide)
- Route
- Oral
- Model Type
- 1-CMT PopPK
- Indication
- Metastatic castration-resistant prostate cancer
- Therapeutic Area
- Oncology
Key Differences
Routes of Administration
OralIV/IMIV/OralIM (LAI)IVVariousOral/LAI
Therapeutic Areas
CardiologyImmunologyInfectious DiseaseTransplantEndocrinologyOncologyPsychiatryObstetricsPulmonologyPlatformCNSMetabolic
Indications
- • Anticoagulation
- • Inflammation/Preterm Labor
- • Inflammation
- • HIV-1 infection
- • Organ Transplant Rejection
- • Heart Failure / Atrial Fibrillation
- • Stroke prevention in atrial fibrillation
- • Heart failure with reduced ejection fraction
- • Type 2 diabetes mellitus
- • CMV Infection
- • HR+/HER2- metastatic breast cancer
- • CML / GIST
- • Chronic lymphocytic leukemia
- • Cholangiocarcinoma
- • Schizophrenia
- • BRCA-mutated ovarian cancer
- • Maternal-Fetal Medicine
- • Idiopathic pulmonary fibrosis
- • Solid Tumors
- • MSSA Infections (Neonates)
- • COVID-19 treatment
- • Multiple myeloma
- • Drug Development
- • Rheumatoid arthritis
- • Organ Transplant
- • EGFR-mutated non-small cell lung cancer
- • Cystic fibrosis
- • Invasive Fungal Infections
- • Transthyretin amyloid cardiomyopathy
- • Obesity/T2DM
- • Metastatic castration-resistant prostate cancer
Disclaimer: This comparison is for educational and research purposes only. Pharmacokinetic parameters are derived from published population PK models and may not reflect individual patient variability. Drug selection and dosing should always be guided by clinical judgment, prescribing information, and applicable guidelines. Not intended for clinical use.